Technical Analysis for NRIX - Nurix Therapeutics, Inc.

Grade Last Price % Change Price Change
grade C 28.38 4.96% 1.34
NRIX closed up 4.96 percent on Friday, October 23, 2020, on 17 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Up Up
Historical NRIX trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
MACD Bullish Signal Line Cross Bullish 0.00%
Wide Bands Range Expansion 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Up 5 Days in a Row Strength 0.00%
20 DMA Resistance Bearish 4.96%
50 DMA Resistance Bearish 4.96%
Inside Day Range Contraction 4.96%
Older End-of-Day Gignals for NRIX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 5% 2 days ago
Rose Above Previous Day's High 2 days ago
Up 3% 2 days ago
60 Minute Opening Range Breakout 2 days ago
Up 2% 2 days ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's lead product candidates in preclinical stage include NX-2127, an orally available Bruton's tyrosine kinase degrader for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B inhibitor for immuno-oncology indications. It also provides DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a class of enzymes that could modulate proteins within the cell. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc.; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was founded in 2009 and is headquartered in San Francisco, California.
Biotechnology Biopharmaceutical Cancer Life Sciences Treatment Of Cancer Sanofi Small Molecule Therapies Gilead Sciences Immune Disorders Bruton's Tyrosine Kinase

Is NRIX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 37.46
52 Week Low 15.21
Average Volume 172,395
200-Day Moving Average 0.00
50-Day Moving Average 27.41
20-Day Moving Average 27.28
10-Day Moving Average 26.08
Average True Range 2.49
ADX 14.8
+DI 24.52
-DI 18.81
Chandelier Exit (Long, 3 ATRs ) 28.45
Chandelier Exit (Short, 3 ATRs ) 30.55
Upper Bollinger Band 33.15
Lower Bollinger Band 21.41
Percent B (%b) 0.59
BandWidth 43.04
MACD Line -0.21
MACD Signal Line -0.31
MACD Histogram 0.1069
Fundamentals Value
Market Cap 1.1 Billion
Num Shares 38.9 Million
EPS -1.82
Price-to-Earnings (P/E) Ratio -15.56
Price-to-Sales 80.84
Price-to-Book 3.42
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 31.86
Resistance 3 (R3) 31.61 30.21 31.28
Resistance 2 (R2) 30.21 29.32 30.33 31.09
Resistance 1 (R1) 29.29 28.77 29.75 29.54 30.89
Pivot Point 27.89 27.89 28.12 28.01 27.89
Support 1 (S1) 26.97 27.00 27.43 27.22 25.87
Support 2 (S2) 25.57 26.45 25.69 25.67
Support 3 (S3) 24.65 25.57 25.48
Support 4 (S4) 24.90